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1. Introduction 
It is now recognized that glucagon and epinephrine 
regulate gluconeogenesis by different mechanisms~ 
Glucagon stimulation of gluconeogenesis appears to 
be mediated via cyclic AMP and the CAMP-dependent 
protein kinase system [ 11, whereas epinephrine is 
believed to stimulate hepatic gluconeogenesis via a 
CAMP-independent cr-adrenergic receptor system [ 11. 
Calcium has been implicated as an important regu- 
lator in the a-adrenergic control of glycogenolysis 
12-41, however its regulatory role in hepatic glucon- 
eogenesis is less well defined [ 11. Intracellular mobili- 
zation of Ca” appears to follow cr-adrenergic stimula- 
tion [5,6]. Moreover hepatic protein phospho~lation 
and inactivation of pyruvate kinase by angiotensin II 
and vasopressin are also Ca2’dependent [7]. The con- 
cept emerging is that protein phosphorylation is prob- 
ably the primary regulator of the key enzymes in the 
control of gluconeogenesis and that either CAMP or 
Ca2+ may modulate it. 
Since some Ca”‘-dependent protein kinases such as 
phosphorylase b kinase [8] and the myosin light chain 
kinase owe their Ca”-dependence to calmodulin [9] 
it was of interest to explore whether calmodulin was 
important in the o-adrenergic control of gluconeogen- 
esis. Pheno~iazine drugs are known to block the 
actions of calmoduhn [IO] trifluoperazine has been 
used as a probe to study the possible involvement of 
calmodulin in the control of insulin secretion from 
isolated pancreatic islets [11{. The purpose of this 
study was to determine whether ol-adrenergic stimula- 
tion of gluconeogenesis could be inhibited by chlor- 
+ To whom correspondence should be addressed 
ElsevierfNorth-Holland Biomedical Press 
promazine and if so whether this was consistent with 
a role for calmodulin in the regulation of hepatic glu- 
coneogenesis. 
2. Materials and methods 
2 .l . Expen~me~ts with ~epato~~tes 
Isolated hepatocytes were prepared from 24 h 
starved rats (250 g) by the procedure in [ 121 as modi- 
fied [ 131. The isolated hepatocytes (1 X lo6 cells/ml) 
were incubated in plastic scintillation vials (20 ml) in 
1.5 ml total vol. Krebs-Henseleit bicarbonate buffer 
containing 1% albumin and 10 mM lactate with 
shaking for 1 h at 37°C and gassed with 02-CO, 
(95:5). Cell viability ranged from 80-95% as judged 
by trypan blue and nigrosin dye exclusion. Neither 
chlorpromazine nor phenylephrine had any measur- 
able effect on cell viability during the course of cell 
incubation. Glucose output was assessed in neutral- 
ized perchloric acid precipitated samples by the glu- 
case-oxidase-peroxidase method [14]. 
2.2. ~adi~~igand binding studies 
Liver plasma membranes for drug binding studies 
were prepared up to step 12 of the procedure in [ 151. 
Plasma membrane protein concentration [ 161 and 
5 ‘nucleotidase [ 171 were measured. [ 3H]Prazosin 
was purified before use by thin-layer chromatography 
on silica gel plates (Anal. Techn. Inc.) using ethyl ace- 
tate:diethyiamine (19:l) mobile phase. Pfasma mem- 
branes were washed with 50 mM Tris-WC1 buffer 
(pH 7.6) (49 000 X g for 15 min at 4°C) and resus- 
pended in the same buffer at -250 pg protein/ml. 
Binding assays conta~ing 50 i.tg protein, f3H]prazosin 
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(33 Cijmmol; final cont. 0.07-0.7 nM) and 50 mM 
Tris-HCl buffer (pH 7.6) in 2 ml final vol. were incu- 
bated for 30 min at 25°C and then washed on 
Whatman GF/B glass tibre filters [ 181. Non-specific 
binding was determined by addition of 10 PM indor- 
amin (a selective (or adrenoceptor agonist at each 
[ 3H]prazosin concentration). Specific binding was 
defined as the difference between total binding and 
non-specific binding, and represented from X0-95% 
of total binding depending on ligand concentration. 
Values for the dissociation constant (Kd) and maximal 
number of binding sites @,a,) for [ “Hlprazosin bind- 
ing were determined using computer-assisted iterative 
curve-fitting procedures [ 191. In drug displacement 
studies sigmoid curves were fitted to the points using 
an iterative procedure utilising the logistic function: 
% Radioligand displaced = 100 [DIP/( [DIP f (IC.& 
where [D] is the concentration of displacing drug and 
P is the slope factor. From the value of the ICsO the 
inhibition constant (pi) was obtained [ZO]. 
2 3. ~erni~a~s 
Chlorpromazine, collagenase (type IV), phenyleph- 
rine and Trizma were obtained from Sigma Chemical 
Co. (St Louis). Angiotensin II amide Arg-vasopressin 
and indoramin were obtained from Ciba, Ferring AB 
(Sweden) and Wyeth Labs, respectively. [3H]Prazosin 
(33 Ci/mmol) was kindly donated by Pfizer UK Ltd. 
3. Results 
Chlorpromazine inhibited phenylephrine (50 PM)- 
stimulated gluconeogenesis over 0.1-10 PM withhalf- 
maximal inhibition at -5 PM. Neither the basal rate of 
gluconeogenesis (25 f 2 1.18 glucose . IO6 cells-‘. h-r) 
(fig.lA) nor the glucagon stimulated ~ILlconeogenesis 
was affected by chlorpromazine (fig.1 B) over this 
range. Angiotensin II (0.1 PM) or vasopressin (46 nM) 
produced 20% and 30% stimulation of gluconeogen- 
esis, respectively (not shown) but again chlorpro- 
mazine was without effect. 
Radioligand binding studies were used to investi- 
gate the possibility that chlorpronlaz~e was inhibiting 
phenylephrine-stimulated gluconeogenesis by acting 
primarily as an cx-adrenoceptor antagonist rather than 
by inhibiting calmodulin. Prazosin is known to be a 
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Fig.1. The effect of chlorpromazine on hepatic gluconeogen- 
esis stimulated by ph~nylcp~ine and glucagon: (A) phenyl- 
ephrine (50 PM); and (B) glucagon (2.7 PM) (*). The data are 
expressed as the %, of the basal gluconeogenic rate measured 
in the absence of hormone and chlorpromazine. Values given 
are the mean * SE for 5 (A) and 3 (B) different hepatocyte 
preparations. 
potent competitive antagonist which acts specifically 
at cy , adrenoceptors [2 11. Here, prazosin was a potent 
~hibitor of phenylephrine-stimulated gluconeogen- 
esis with complete inhibition of the process being 
obtained at 10 nM prazosin (fig.2). These results are 
consistent with the finding that prazosin is a potent 
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Fig.2. The effect of prazosin on phenylephrine-stimulated gluconeogenesis. Hepatocytes were incubated with (o) and without (0) 
phenylephrine (SO PM). Results shown for 1 expt. 
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Fig.3. Scatchard plot of specific [ 3H]prazosin binding to 
plasma membranes from rat liver. Each point is the mean value 
of duplicate determination of 2 expt. The lines are those of 
best fit determined by the iterative procedure [ 191: (0) con- 
trol [ ‘H]prazosin binding, Kd = 17.2 tM, B,,, = 1.44 pmol/ 
mg protein;(o) binding in the presence of 4 nM chloropro- 
maZine,Kd = 239 tM,B,,, = 1.16 pmol/mg protein. 
inhibitor of epinephrine stimulated phosphorylase 
activity in isolated hepatocytes [22]. [3H]Prazosin of 
high specific activity was used to label (Y, adrenocep- 
tors in purified preparations of rat liver plasma mem- 
branes to study whether chlorpromazine could dis- 
place it from the a! receptor. [ ‘H]Prazosin binding to 
rat liver plasma membranes was rapid, saturable and 
reversible. Equilibrium studies revealed that the bind- 
ing site has a K, of 17.2 fM and a B,, of 1.44 pmol/ 
mg protein (fig.3). In the presence of a low cencentra- 
tion of chlorpromazine (4 nM) the K, for [ 3H]pra- 
zosin binding was increased -14-fold to 239 fM with 
only a small reduction in B,, to 1 .16 pmol/mg pro- 
tein. These results are consistent with chlorpromazine 
acting as a potent competitive antagonist of [ 3H]pra- 
zosin binding. Increasing concentrations of either 
chlorpromazine or trifluoperazine produced concen- 
trationdependent inhibition of [ 3H] prazosin binding 
(fig.4) with Ki-values of 0.77 and 4.16 nM, respec- 
tively. Hill plots of the displacement curves had gradi- 
ents near unity indicating a lack of cooperativity in 
binding. 
Inhibition of [ 3H]prazosin binding by either chlor- 
promazine or trifluoperazine was independent of Ca”. 
The Ki-values in the presence of either Ca*+ (100 /JIM) 
or EGTA (1 mM) were 0.75 and 1.05 nM for chlor- 
promazine and 4.17 and 4.03 nM for trifluoperazine, 
respectively. 
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Fig.4. Displacement of [ ‘Hlprazosin binding from rat liver plasma membranes by phenothiazine drugs: (A) Effect of chlorpro- 
mazine alone (0) and in the presence of 100 ,uM CaZ+ (0) or 1 mM EGTA (A). Curves are those of best fit determined by the itera- 
tive procedure [19]. (B) Effect of trifluoperazine alone (0) and in the presence of 100 PM Ca’+ (~:) or 1 mhl EGTA (A). 
4. Discussion 
These results show that cu-adrenergic-stimulated 
gluconeogenesis from lactate in isolated hepatocytes 
can be blocked by chlorpromazine with half-maximal 
inhibition occurring at -5 PM. Similar concentrations 
of chlorpromazine are required to inhibit phenyleph- 
rine-stimulated gluconeogenesis, calmodulinilepen- 
dent phosphodiesterase [lo] and phosphorylase b 
kinase 1231. In contrast, glucagon-stimulated glucon- 
eogenesis was unaffected by chlorpromazine over 
10 nM-IO FM. The inhibition of phenylephrine-stim- 
ulated g~u~oneogenesis occurs at con~ent~tions of 
chlorpromazine below those required to observed non- 
saturating uptake of the drug into isolated hepato- 
cytes [24]. 
Although these results would appear to be consistent 
with the concept that calmodulin may be involved, 
chlorpromazine failed to inhibit either angiotensin II- 
or vasopressin-stimulated g~u~oneogel~~sis. Both of 
these hormones require Ca” to inactivate hepatic 
pyruvate kinase [7]. The results of these radioligand 
binding studies suggest hat chlorpromazine inhibition 
of phenylephrine-stimulated gluconeogenesis results 
entirely from its a-antagonist activity at the cell mem- 
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brane rather than from effects on calmoduhn. The 
binding of the highly selective CI~ adrenoceptor antag- 
onist [3H]prazosin to the liver plasma membrane 
fraction was potently inhibited by chlorpromazine. 
Scatchard plots of [ 3H]prazosin binding conducted in 
the presence of a low ~oncelltratioil of clllorprol~tazine 
showed increases in Kd with no significant change in 
B,,, indicating competitive inhibition. 5ispia~elnent 
of a saturating concentration of [ 3H]prazosin by 
increasing concentrations of chlorpromazine and tri- 
fluoperazine revealed that both drugs had high potency 
at hepatic Q, adrenoceptors. Radiolabelled chlorpro- 
mazine of s~lf~~iently high specific activity was not 
available to confirm that phenylephrine could block 
its binding. 
A further possibility is that calmodulin could be a 




Chlorpromazine was X-times more potent than 
tri~uo~~razil~e in displaying bound [“Hfprazosin 
which is the reverse order of potency to that 
observed against calmodulin~ependent phospho- 
diesterase [101. 
Displacement of bound [ 3H]prazosin by both 
chlorpromazine and trifluoperazine was indepen- 
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dent of Ca*+ in contrast to the Ca”-dependent 
binding of phenothiazines to calmodulin [lo]. 
These results indicate that chlorpromazine and tri- 
fluoperazine inhibit ol-adrenergicstimulated gluconeo- 
genesis by acting as o-antagonists at the plasma mem- 
brane level. These observations together with the 
report of a calmodulin-independent protein kinase 
[25] inhibited by chlorpromazine highlight the diffi- 
culties in attempting to use phenothiazine drugs as 
probes for calmodulin function in cellular systems. 
Furthermore, when calmodulin is bound as the 6 -sub- 
unit of muscle phosphorylase b kinase it is relatively 
insensitive to phenothiazine drugs [23]. 
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Note added in proof 
Blackmore et al. [26] have recently reported that 
inhibition of phenylephrine stimulated activation of 
hepatic phosphorylase a by chlorpromazine and tri- 
fluoroperazine was due to a-antagonist activity. While 
we agree with the conclusions of this report regarding 
cr-adrenergic ontrol of hepatic gluconeogenesis we 
feel that their use of [3H]epinephrine as a l&and to 
identify a-adrenoreceptors in liver plasma membranes 
was inappropriate for two reasons: 
(9 
(ii) 
[3H] Epinephrine labels predominantly a2 recep- 
tors in the high affinity (&H) state which con- 
stitute <20% of the total hepatic cy adrenorecep- 
tors [27] ; 
Evidence from this study would indicate that the 
adrenoreceptor controlling ghtconeogenesis of 
the or-type. ^ 
The use of the specific a-antagonist ([“HI prazosin) as 
a ligand to identify a,-receptors in liver plasma mem- 
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